Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator dictionary.testing.TypeOfStudy dictionary.testing.PhasesOfClinicalTrialsForDrugs
N202603079 Effects of Different Treatment Strategies on the Incidence of Urinary Tract Infection in Patients with Asymptomatic Bacteriuria During the Acute to Subacute Phase After Stroke: A Double-Blind Randomized Controlled Trial New Drug (New Indication) NA
N202603097 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1) New Drug Phase Ⅲ
N202603098 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2) New Drug Phase Ⅲ
N202603099 An open-label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301 New Drug Phase Ⅱ
N202603124 Dostarlimab, cisplatin and etoposide in combination with radiotherapy in sandwich sequence for small cell neuroendocrine cervical carcinoma （DICER trial）: Taiwanese Gynecologic Oncology Group (TGOG) 1012 New Drug Phase Ⅱ
N202603151 A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction New Drug Phase Ⅲ
N202603152 A Phase 3, Randomized, Double-blind Study of Adjuvant MK-1084 Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) versus Adjuvant Placebo Plus MK-3475A in Participants with Completely Resected Stage IIA-IIIB (N2), KRAS G12C-mutant Non-small Cell Lung Cancer following Receipt of Either Neoadjuvant Pembrolizumab Plus Chemotherapy or Adjuvant Chemotherapy (KANDLELIT-013) New Drug Phase Ⅲ
N202603153 A Phase 1, open-label, dose-escalation study (ELEVATE-1) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven autoimmune rheumatic diseases (ARD) New Drug Phase Ⅰ
N202603154 Feasibility, toxicity, and biological effect of bortzomib with chemotherapy in patients with malignant rhabdoid tumors New Drug Academic Research
1 2 41 42 43 44 45 46 47 51 52 / 52

TOP